Soft tissue sarcoma · 9 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Epirubicin and Ifosfamide Variant #03 | — | R 27 949 | 21d | — | — | ~7 | ~R 195 643 indirect | — |
Doxorubicin and Ifosfamide Variant #01 | — | R 23 121 | 21d | — | — | ~6 | ~R 138 724 indirect | — |
Doxorubicin, Ifosfamide, RT Variant #01 | — | R 19 517 | 21d | — | — | ~6 | ~R 116 314 indirect | — |
MAID Variant #01 | — | R 17 519 | 21d | — | — | ~2 | ~R 35 039 indirect | — |
Docetaxel and Gemcitabine Variant #01 | — | R 6 266 | 21d | ~6.2 mo | — | ~9 | ~R 56 391 PFS proxy · indirect | 1 |
Dacarbazine and Gemcitabine Variant #01 | — | R 4 793 | 14d | — | ~16.8 mo | ~13 | ~R 62 314 PFS proxy · indirect | 1 |
Gemcitabine and Vinorelbine Variant #01 | — | R 4 259 | 21d | — | ~6.7 mo | ~2 | ~R 8 518 PFS proxy · indirect | 2 |
Dacarbazine and Doxorubicin Variant #01 | — | R 1 489 | 21d | — | — | ~2 | ~R 2 979 indirect | — |
Doxorubicin and Olaratumab Variant #01 Partial | — | R 789 | 21d | — | ~20.4 mo | ~9 | ~R 6 311 PFS proxy · indirect | 1 |
9 of 9 regimens shown